MAPT and Alzheimer disease: This suggests that plasma P‐tau217 is not necessarily elevated due to tau accumulation in pure non‐AD tauopathies, supporting that the increase in plasma P‐tau217 is specific to AD (and may require plaque deposition in addition to tau accumulation).